A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma

Leukemia

Volumn 31, Issue 1, 2017, Pages 241-244

  Reddy, N M ^a   Greer, J P ^a   Morgan, D S ^a   Chen, H ^a   Park, S I ^b   Richards, K L ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; RITUXIMAB; ANTINEOPLASTIC AGENT; THALIDOMIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LETTER; MAINTENANCE CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; THROMBOSIS; ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RISK ASSESSMENT; RITUXIMAB; SURVIVAL RATE; THALIDOMIDE; YOUNG ADULT;

EID: 84991039497     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.255     Document Type: Letter

References (15)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994
2. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861
3. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-5992
4. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45
5. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008; 57: 1849-1859
6. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242
8. Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-1867
9. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013; 369: 1681-1690
10. Crump MLS, Fayad L, Lee J, Rocco AD. A Phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the prelude trial. J Clin Oncol 2016; 34: 2484-2492
11. Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P et al. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate-or high-risk diffuse large B-cell lymphoma. Leuk Lymphoma 2016; 57: 216-218
12. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957
13. Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014; 15: 730-737
14. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 2015; 33: 251-257
15. Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA et al. Eventfree survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014; 32: 1066-1073.